Cargando…

Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients

Severe COVID-19 is associated with a systemic hyperinflammatory response leading to acute respiratory distress syndrome (ARDS), multi-organ failure, and death. Galectin-3 is a ß-galactoside binding lectin known to drive neutrophil infiltration and the release of pro-inflammatory cytokines contributi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cervantes-Alvarez, Eduardo, la Rosa, Nathaly Limon-de, la Mora, Moises Salgado-de, Valdez-Sandoval, Paola, Palacios-Jimenez, Mildred, Rodriguez-Alvarez, Fatima, Vera-Maldonado, Brenda I., Aguirre-Aguilar, Eduardo, Escobar-Valderrama, Juan Manuel, Alanis-Mendizabal, Jorge, Méndez-Guerrero, Osvely, Tejeda-Dominguez, Farid, Torres-Ruíz, Jiram, Gómez-Martín, Diana, Colborn, Kathryn L., Kershenobich, David, Huang, Christene A., Navarro-Alvarez, Nalu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813958/
https://www.ncbi.nlm.nih.gov/pubmed/35115644
http://dx.doi.org/10.1038/s41598-022-05968-4
Descripción
Sumario:Severe COVID-19 is associated with a systemic hyperinflammatory response leading to acute respiratory distress syndrome (ARDS), multi-organ failure, and death. Galectin-3 is a ß-galactoside binding lectin known to drive neutrophil infiltration and the release of pro-inflammatory cytokines contributing to airway inflammation. Thus, we aimed to investigate the potential of galectin-3 as a biomarker of severe COVID-19 outcomes. We prospectively included 156 patients with RT-PCR confirmed COVID-19. A severe outcome was defined as the requirement of invasive mechanical ventilation (IMV) and/or in-hospital death. A non-severe outcome was defined as discharge without IMV requirement. We used receiver operating characteristic (ROC) and multivariable logistic regression analysis to determine the prognostic ability of serum galectin-3 for a severe outcome. Galectin-3 levels discriminated well between severe and non-severe outcomes and correlated with markers of COVID-19 severity, (CRP, NLR, D-dimer, and neutrophil count). Using a forward-stepwise logistic regression analysis we identified galectin-3 [odds ratio (OR) 3.68 (95% CI 1.47–9.20), p < 0.01] to be an independent predictor of severe outcome. Furthermore, galectin-3 in combination with CRP, albumin and CT pulmonary affection > 50%, had significantly improved ability to predict severe outcomes [AUC 0.85 (95% CI 0.79–0.91, p < 0.0001)]. Based on the evidence presented here, we recommend clinicians measure galectin-3 levels upon admission to facilitate allocation of appropriate resources in a timely manner to COVID-19 patients at highest risk of severe outcome.